...are needed, but said it does not have plans for additional trials at this time. Canyon Pharmaceuticals AG...

...requested by shareholder HBM BioVentures. The new members are: Thomas Rinderknecht, chairman of cardiovascular company Canyon Pharmaceuticals AG...

...requested by shareholder HBM BioVentures. The new members are: Thomas Rinderknecht, chairman of cardiovascular company Canyon Pharmaceuticals AG...

...part of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.); and Thomas Rinderknecht, chairman of cardiovascular company Canyon Pharmaceuticals AG...

...part of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.); Seng Chin Mah, CEO of cardiovascular company Canyon Pharmaceuticals AG...

...plc (LSE:GSK; NYSE:GSK), would add expertise in commercial strategy, while Mah, CEO of cardiovascular company Canyon Pharmaceuticals AG...

...former managing director and SVP of GlaxoSmithKline Germany; Seng Chin Mah, CEO of cardiovascular company Canyon Pharmaceuticals AG...

...DVT in patients undergoing hip replacement surgery and as Revasc in Europe for DVT prophylaxis. Canyon Pharmaceuticals AG...

...an anticoagulant to prevent or treat thrombosis in patients with or at risk for HIT. Canyon Pharmaceuticals AG...

...patients in clinical trials used an average of two vials per day for nine days. Canyon Pharmaceuticals...